Opyl Ltd. (AU:PKY)
ASX:PKY
Want to see AU:PKY full AI Analyst Report?
PKY Stock Chart & Stats
AU$0.03
--
Market closed
AU$0.03
--
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.05
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.13M
Market Cap
AU$22.46M
Enterprise ValueAU$14.22M
Total Cash (Recent Filing)AU$580.84K
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.60
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding607,077,760
10 Day Avg. Volume406,454
30 Day Avg. Volume1,132,050
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-21.63
Price to Sales (P/S)208.90
P/FCF Ratio-4.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AI-driven Life Sciences PlatformOpyl’s core focus on AI/ML for clinical trials and drug development aligns with a durable industry shift toward data-driven R&D. That specialization creates potential for sticky, high-value B2B relationships as sponsors and CROs increasingly adopt analytics to speed recruitment and decision-making.
Multiple B2B Revenue LeversHaving subscription/licensing, services, and partnership/milestone channels provides structural flexibility to diversify income. Over time this mix can smooth revenue volatility, allow entry-level services to seed platform adoption, and support upsell into higher‑margin recurring contracts.
Asset-light Software/platform ModelA software and platform orientation implies low incremental capital intensity versus biotech product makers. If Opyl can scale users and data, marginal economics should improve materially, enabling higher gross margins and international expansion without large fixed‑asset investment.
Bears Say
Sharp Revenue ContractionAn ~86% revenue decline signals severe loss of customer traction or contract reversals, undermining scale economics and undermining the path to sustainable margins. Persistent top‑line shrinkage raises the hurdle for recovering fixed costs and achieving profitable unit economics over months to quarters.
Persistent Negative Cash FlowConsistent operating and free cash flow deficits indicate the business is not self‑funding. Ongoing cash burn requires external capital to sustain operations, increasing dilution risk and potentially forcing tradeoffs that impair R&D or commercial investment critical for long‑term growth.
Negative Equity And Rising DebtNegative shareholders’ equity and increasing debt signal a fragile capital structure that limits financial flexibility. This elevates refinancing and covenant risks, constrains strategic investments, and can make the company vulnerable if revenue recovery takes longer than expected.
Opyl Ltd. News
PKY FAQ
What was Opyl Ltd.’s price range in the past 12 months?
Opyl Ltd. lowest share price was AU$0.01 and its highest was AU$0.05 in the past 12 months.
What is Opyl Ltd.’s market cap?
Opyl Ltd.’s market cap is AU$22.46M.
When is Opyl Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Opyl Ltd.’s earnings last quarter?
Currently, no data Available
Is Opyl Ltd. overvalued?
According to Wall Street analysts Opyl Ltd.’s price is currently Overvalued.
Does Opyl Ltd. pay dividends?
Opyl Ltd. does not currently pay dividends.
What is Opyl Ltd.’s EPS estimate?
Opyl Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Opyl Ltd. have?
Opyl Ltd. has 607,077,760 shares outstanding.
What happened to Opyl Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Opyl Ltd.?
Currently, no hedge funds are holding shares in AU:PKY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Opyl Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.74%
12-Months-Change
Fundamentals
Return on Equity
-1122.02%
Trailing 12-Months
Asset Growth
129.09%
Trailing 12-Months
Company Description
Opyl Ltd.
Pathkey.AI Ltd, a digital health company, involves artificial intelligence (AI) to improve clinical trials and predicting outcomes for patients in Australia. The company offers TrialKey, an AI-driven clinical trial optimization and success prediction platform, that simulate and optimize trial designs. It also provides TrialGen, an AI-powered tool streamlines clinical trial design process. The company serves biopharma, MedTech, government, and healthcare organizations. The company was formerly known as Opyl Limited and changed its name to Pathkey.AI Ltd in August 2025. Pathkey.AI Ltd was incorporated in 1994 and is based in Sydney, Australia.
Technical Analysis
Global Health Limited
―
―
Singular Health Group Ltd
―
HitIQ Limited
―
InteliCare Holdings Limited
―
Options Prices
Currently, No data available
---